AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00489593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
Study NCT00722943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Massage Therapy
Description: Tactile stimulation and massage will be done by a licensed therapist
Study NCT00722943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: The infant will not be touched by the therapist.
Study NCT02085161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to tiotropium + olodaterol
Description: comparator
Study NCT02085161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium+olodaterol
Description: tiotropium 5 mcg once daily
Study NCT02085161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium +olodaterol
Description: olodaterol 5 mcg once daily fixed dose combination
Study NCT02085161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: tiotropium 5 mcg once daily fixed dose combination
Study NCT01394003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702
Description: administered orally
Study NCT03036202 — intervention group
Intervention type: DRUG
Intervention: Epinephrine
Description: This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
Study NCT00584636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pulmicort respules
Description: pulmicort respules 0.5 mg twice a day for 28 days versus placebo
Study NCT05510232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A treatment group that will watch a non-VR video via an iPad
Description: The iPad is a tablet computer first offered by Apple in 2010.The device resembles a much larger version of Apple's iPhone or its iPod Touch, and is about the same size as a magazine.The iPad uses the same operating system as the Apple iPhone, and uses very similar hardware. iPad will be used to deliver non VR video to patients.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups.
Study NCT05510232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A treatment group that will have headset on and will watch a non-VR video
Description: Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver non VR video to patients. Headset will be administered before intervention and removed at the completion of the intervention unless patient requests otherwise. Patients visual field will not change with head motion and will remain static throughout cast removal or pin/suture removal.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups.
Study NCT05510232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A treatment group that will be immersed in the VR game (Bear Blast) via the headset.
Description: VR using the Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver VR images and sound. Patients will watch a 15-minute VR experience called Bear Blast. Bear Blast is an immersive, 360-degree, game experience that takes place in a fantasy world where the user attempts to shoot balls at a wide range of moving objects by gently maneuvering his or her head toward the targets. Bear Blast is a nonviolent and noncompetitive game that incorporates motivational music and features positively reinforcing sounds, animation, and direct messages to patients. Bear Blast will be used as the standardized game for all patients in the VR group of both study arms. The VR reality Samsung Oculus headset can be controlled entirely via head motion and does not involve the use of patients extremities. iPad will be set up and held for patients in the iPad group.
Study NCT01647217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terpinen-4-ol
Description: Lid scrub once or twice per day for one month.
Study NCT01647217 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lid scrub once or twice per day for one month
Study NCT02949284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT02949284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Receptor Antagonist ARN-509
Description: Given PO
Study NCT02949284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen Receptor Antagonist ARN-509
Description: Given PO
Study NCT02949284 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin-releasing Hormone Analog
Description: Given SC
Study NCT02949284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT02949284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02949284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02949284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02949284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02949284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT02949284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT03995602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dragon fruit juice drink
Description: Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
Study NCT03995602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drink with macro- and micro-nutrient matched against the intervention drink.
Study NCT03570710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous tranexamic acid
Description: 1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
Study NCT03570710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: 2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
Study NCT03570710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
Study NCT02532803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Pelvic MRI scan assessment
Description: A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
Study NCT02850913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: * 115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~* Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety
Study NCT02850913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: - Placebo (matching capsules containing no active ingredients)
Study NCT02698553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCl XL tablet 150mg
Description: The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
Study NCT02698553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCl XL tablet 300mg
Description: The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
Study NCT00997776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive resistance exercise
Description: lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
Study NCT00997776 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
Study NCT02298010 — intervention group
Intervention type: DRUG
Intervention: Capecitabine, oxaliplatin
Study NCT03349034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
Study NCT03349034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local Saline Infusion
Description: Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
Study NCT01065987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Tizanidine HCl Tablets 4 mg
Study NCT01065987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tizanidine
Description: Tizanidine HCl Tablets 4 mg
Study NCT03261752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 \&STK31 by RTPCR.
Study NCT04299789 — intervention group
Intervention type: OTHER
Intervention: Validating the Military Service Identification Tool
Description: This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
Study NCT04530084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMNI Surgical System
Description: Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
Study NCT02595489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: Daily oral supplement provided by study investigators
Study NCT02449148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: diet intervention to reduce the risk for obesity associated diseases
Study NCT00753649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Intramuscular, three doses
Study NCT00753649 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Intramuscular, three doses
Study NCT05411952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy and carbohydrate counting education
Description: Children and their mothers have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
Study NCT05411952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy and carbohydrate counting education
Description: Only children have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
Study NCT05411952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Control group didn't receive any intervention by trained dietitian. Furthermore they continued their routine health controls.
Study NCT04475302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine (Freeze-dried)
Description: single dose of BCG vaccine (Freeze-dried) manufactured by Serum Institute of India, Pune. The composition of BCG vaccine is Live, attenuated BCG (Bacillus Calmette-Guerin Strain). (Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) with Diluent: Sodium Chloride Injection I.P.)
Study NCT04531930 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: Colorectal surgery, mainly total proctocolectomy.
Study NCT04531930 — intervention group
Intervention type: PROCEDURE
Intervention: enhanced colonoscopy
Description: Colonoscopic treatment and surveillance in every 3 months.
Study NCT04531930 — intervention group
Intervention type: OTHER
Intervention: self choosed methods
Description: A patient chooses a method for himself other than surgery.
Study NCT02117661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine capsules
Description: Oral
Study NCT02117661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose capsules
Description: oral
Study NCT00967421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol
Description: BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
Study NCT00967421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
Study NCT00967421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo drink containing no alcohol + placebo pill
Study NCT04490876 — intervention group
Intervention type: PROCEDURE
Intervention: 3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method
Description: After the injection of Brilliant Blue-G (BBG) into the vitreous cavity, the epiretinal membrane (ERM) with cellular proliferation on the surface of the retina did not stain clearly, while the internal limiting membranes did stain clearly. We peeled off the internal limiting membrane (ILM) underlying the ERM using the ILM forceps for the macular area and the serrated forceps for the remaining ILM beyond the vascular arcades (Grieshaber, Alcon Laboratories, Inc., Fort Worth, Texas (Figure1) and enhanced membrane viewing with filters on the Ngenuity system. Restaining with BBG was needed and perfluorocarbon liquid PFCL was injected with a coaxial Dual Bore cannula (MedOne) to flatten the retina.
Study NCT03200288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HL-01: high and low molecular weight hyaluronic acid
Description: 2 ml intra-articular single injection
Study NCT03200288 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml intra-articular single injection
Study NCT03108469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IONIS-PKKRx (ISIS 546254)
Description: Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
Study NCT03108469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
Study NCT04342533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium fiber laser enucleation of the prostate
Description: enucleation of the BPH according to standard procedure protocol
Study NCT04342533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Description: enucleation of the BPH according to standard procedure protocol
Study NCT04021641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Speech recognition in noise
Description: Measurement of speech recognition performance in noise
Study NCT03419923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: two stage regional citrate
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
Study NCT03419923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: two stage regional citrate
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
Study NCT03419923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one stage regional citrate
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
Study NCT03419923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one stage regional citrate
Description: 4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
Study NCT04539132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABI Wellness Program
Description: The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
Study NCT03631888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: preoperative abdominal ultrasound examination
Description: Performing preoperative abdominal ultrasound examination in patients that will be scheduled for elective laparoscopic surgery for any gynecologic indication
Study NCT04913935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle-Skeleton Ultrasonography
Description: postero-anterior radiography
Study NCT00772317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: High Intensity Focused Ultrasound
Study NCT01022528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1 mg/kg)
Study NCT01022528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg)
Study NCT01022528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02796183 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Subconjunctival bevacizumab (Altuzan)
Description: Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
Study NCT04250909 — intervention group
Intervention type: DEVICE
Intervention: Passeo-18
Description: POBA
Study NCT04250909 — intervention group
Intervention type: DEVICE
Intervention: Passeo-18 Lux
Description: DCB
Study NCT05295069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A nursing care program was applied for the intervention group under the guidance of Levine's conservation model.
Description: Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
Study NCT04646044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Administered as an intravenous infusion
Study NCT04646044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT04646044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT04646044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an intravenous infusion
Study NCT02528552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LH80 PRO
Study NCT02528552 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Study NCT02939443 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: supine- and prone-position Computed Tomography